Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434556 | 0.92 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL19407910 | 0.89 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL16940028 | 0.88 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL18610413 | 0.88 | ATM (0.45) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL12463688 | 0.88 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL19686996 | 0.87 | TDP1 (0.49) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL21147462 | 0.87 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL15434662 | 0.85 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2OPRM1USP2THRB | |
| SCHEMBL15434630 | 0.85 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 | |
| SCHEMBL15434647 | 0.85 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| EP-4137572-A1 | CHIRAL DESIGN | Wave Life Sciences Ltd. (SG) | 2023-02-22 | — | — | EP | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-06-23 | — | — | US | disclosed |
| US-20210130821-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2021-05-06 | — | — | US | disclosed |
| US-10590413-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2020-03-17 | — | — | US | disclosed |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2019-11-19 | — | — | US | disclosed |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192664-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
| US-20170037399-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2017-02-09 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2014012081-A2 | CHIRAL CONTROL | ONTORII, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130821-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885SMN1; SMN2 695/4885KMT2A 2211/4885 |
| US-20170275621-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885SMN1; SMN2 695/4885KMT2A 2211/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885SMN1; SMN2 695/4885KMT2A 2211/4885 |
| US-10479995-B2 | Oligonucleotide compositions and methods thereof | RNGTT, NSUN2, POLRMT | ALDH1A1 3314/4885SMN1; SMN2 320/4885KMT2A 918/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885SMN1; SMN2 695/4885KMT2A 2211/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885SMN1; SMN2 695/4885KMT2A 2211/4885 |
| US-10590413-B2 | Chiral control | RNGTT, POLI, NSUN3 | ALDH1A1 2867/4885SMN1; SMN2 695/4885KMT2A 2211/4885 |
| US-20220195429-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | ALDH1A1 3314/4885SMN1; SMN2 320/4885KMT2A 918/4885 |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | ALDH1A1 3314/4885SMN1; SMN2 320/4885KMT2A 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.